CA3240281A1 — Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
Assigned to Pharmacyclics LLC · Expires 2011-12-08 · 14y expired
What this patent protects
Claims 1. Use of a compound for treating diffuse large B-cell lymphoma in an individual in need thereof, wherein the compound has the structure: o . N H2 . N \ "N N N oN ---,C--o wherein the individua…
USPTO Abstract
Claims 1. Use of a compound for treating diffuse large B-cell lymphoma in an individual in need thereof, wherein the compound has the structure: o . N H2 . N \ "N N N oN ---,C--o wherein the individual achieves a stable disease, a partial response, or a complete response. 2. Use of a compound in the manufacture of a medicament for treating diffuse large B-cell lymphoma in an individual in need thereof, wherein the compound has the structure: o . N H2 . N \ N N N/ oN ---,C-o wherein the individual achieves a stable disease, a partial response, or a complete response. 3. Use of a compound and an anti-CD20 antibody selected from rituximab and ofatumumab for treating diffuse large B-cell lymphoma in an individual, wherein the compound has the structure: Date regue/date received 2024-06-03
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.